Kaopectate Labeling Now Excludes Children’s Dosing, Pfizer Says
This article was originally published in The Tan Sheet
Executive Summary
Pfizer has removed dosing instructions for children under 12 from its Kaopectate antidiarrheal products in compliance with the OTC final monograph for the product class, according to the company